Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
363 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (18)
  • (-) Currently Recruiting (2)
  • Closed (16)

Medical Condition

  • Show all (363)
  • Addiction (2)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (2)
  • Blood Disorders (1)
  • Bone & Muscle (2)
  • Cancer (109)
  • COVID-19 (Coronavirus) (10)
  • Diabetes (9)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (44)
  • Heart Disease (25)
  • Infectious Disease (11)
  • Liver Disease (14)
  • Lung Disease (3)
  • Neurological Disorders (45)
    • Alzheimer's Disease (7)
    • Brain Tumors (12)
    • Cerebral Palsy (2)
    • Dementia (3)
    • Huntington's Disease (2)
    • Multiple Sclerosis (4)
    • Neuromuscular (2)
    • (-) Neuropathy (1)
    • Parkinson's Disease (2)
  • Nutrition (1)
  • Obesity (8)
  • Obstetrics & Gynecology (12)
  • Pediatrics (26)
  • Psychiatric Disorders (8)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
    • (-) Kidney Transplant (1)
    • Liver Transplant (9)
    • Stem Cell Transplant (3)
Displaying 1 - 2 of 2

A Study to Test the Effects and Safety of Riliprubart in People with Chronic CIDP for Which the Usual Treatment Does Not Work

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Currently Recruiting
This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
Read More

Study of Siplizumab-Based Treatment in Patients Undergoing Kidney Transplant (PANORAMA)

Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Currently Recruiting
This is a 60-month adaptive to evaluate three siplizumab-based treatment regimens in kidney transplant recipients. The purpose of this research study is to see if the anti-rejection medications that patients normally take after transplant can be reduced or stopped completely by using several medications including the investigational drug siplizumab in the…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science